Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bristol-Myers Squibb Co - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
BMY
New York
2834
https://www.bms.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bristol-Myers Squibb Co
Bristol Myers (BMY) Announces Upbeat Data From NSCLC Study
- Jun 5th, 2023 2:22 pm
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
- Jun 4th, 2023 12:00 pm
3 Dividend Stocks You Can Buy Without Any Hesitation
- Jun 3rd, 2023 10:14 am
10 Stocks Jim Cramer and Hedge Funds Have In Common
- Jun 2nd, 2023 7:55 pm
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
- Jun 2nd, 2023 5:17 pm
Bristol-Myers Squibb Company (NYSE:BMY) is largely controlled by institutional shareholders who own 78% of the company
- Jun 2nd, 2023 11:00 am
The Zacks Analyst Blog Highlights NVIDIA, Bristol-Myers Squibb, ICICI Bank, Palo Alto and Walgreens Boots Alliance
- Jun 2nd, 2023 8:59 am
Bristol Myers Squibb (BMY) Gains But Lags Market: What You Should Know
- Jun 1st, 2023 9:45 pm
Top Analyst Reports for NVIDIA, Bristol-Myers Squibb & ICICI Bank
- Jun 1st, 2023 8:52 pm
Bristol Myers (BMY) Loses 10.5% Year-to-Date: What Lies Ahead?
- Jun 1st, 2023 4:46 pm
Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More
- Jun 1st, 2023 3:35 pm
15 Best Healthcare Stocks To Buy Now
- Jun 1st, 2023 2:04 pm
3 Top Stocks That Just Went on Sale
- Jun 1st, 2023 1:00 pm
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
- Jun 1st, 2023 10:59 am
Bristol Myers' (BMY) Lung Cancer Drug NDA Gets Priority Review
- May 31st, 2023 4:09 pm
Is Bristol Myers Squibb a Top Dividend Stock?
- May 31st, 2023 3:15 pm
Bristol Myers Squibb to Hold R&D Day on September 14
- May 31st, 2023 10:59 am
Bristol-Myers Squibb Breaks a Key Support Area: What's Next?
- May 30th, 2023 4:50 pm
Bristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
- May 30th, 2023 1:24 pm
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
- May 30th, 2023 10:59 am
Scroll